US 7,550,155 B2
	Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
Zhong Zhang, Sudbury, Mass. (US); Orn Almarsson, Shrewsbury, Mass. (US); and Hongming Chen, Acton, Mass. (US)
Assigned to Transform Pharmaceuticals Inc., Lexington, Mass. (US)
Filed on Jan. 28, 2004, as Appl. No. 10/766,631.
Application 10/766631 is a continuation in part of application No. 10/629308, filed on Jul. 29, 2003.
Application 10/629308 is a continuation in part of application No. 10/677747, filed on Oct. 02, 2003.
Claims priority of provisional application 60/485354, filed on Jul. 07, 2003.
Claims priority of provisional application 60/470403, filed on May 14, 2003.
Claims priority of provisional application 60/464314, filed on Apr. 21, 2003.
Claims priority of provisional application 60/462450, filed on Apr. 11, 2003.
Claims priority of provisional application 60/443490, filed on Jan. 29, 2003.
Claims priority of provisional application 60/436979, filed on Dec. 30, 2002.
Claims priority of provisional application 60/422195, filed on Oct. 29, 2002.
Claims priority of provisional application 60/399490, filed on Jul. 29, 2002.
Claims priority of application No. PCT/US03/23512 (WO), filed on Jul. 29, 2003; and application No. PCT/US03/31086 (WO), filed on Oct. 02, 2003.
Prior Publication US 2004/0265388 A1, Dec. 30, 2004
Int. Cl. A61K 9/14 (2006.01)

U.S. Cl. 424—486

48 Claims

1. An aqueous formulation consisting essentially of, on a gram per 100 ml (reported as %) basis: 1-2% 2,6-diisopropylphenol; water; and up to 15% excipients, wherein said excipients consist essentially of 2% to 6% polyethylene glycol (PEG), from 5% to 9% poloxamer 188, and optionally, one or more pH modifiers, stabilizers, or tonicity modifiers, and wherein said formulation is an aqueous solution including less than 1% lipids and being clear to the naked eye.